Healthcare provider profile · identity verified

Alan Hardwicke, MD

Allopathic & Osteopathic Physicians|Internal Medicine · BALLINGER, TX · NPI 1912969627

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Alan Hardwicke, MD received $55.61 in general payments during 2025 across 3 reported records.

AstraZeneca Pharmaceuticals LP accounted for 72.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Brilinta by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Farxiga by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$55.61

3 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$40.39	72.6%	2	2025
Lilly USA, LLC	Unresolved — no canonical attribution shown	$15.22	27.4%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$55.61	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
FARXIGA Normalized: farxiga	Drug	AstraZeneca Pharmaceuticals LP	$40.39	2	2025
Source payment records 2025-03-05 · AstraZeneca Pharmaceuticals LP · $18.22 · Open Payments source 2025-07-16 · AstraZeneca Pharmaceuticals LP · $22.17 · Open Payments source
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$15.22	1	2025
Source payment records 2025-10-01 · Lilly USA, LLC · $15.22 · Open Payments source
ZEPBOUND Normalized: zepbound	Drug	Lilly USA, LLC	$15.22	1	2025
Source payment records 2025-10-01 · Lilly USA, LLC · $15.22 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
FARXIGA farxiga	2025	Farxiga	2024	103	exact normalized	Medicare Part D
MOUNJARO mounjaro	2025	Mounjaro	2024	13 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	BRILINTA open payments reported associated product	CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430	Brilinta · 2024 Exact normalized brand match · 1 Part D row	48	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	103	13
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	105	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	61	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	698	105
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	673	82
Gabapentin	Gabapentin	663	95
Potassium Chloride	Potassium Chloride	637	102
Lisinopril	Lisinopril	535	104
Amlodipine Besylate	Amlodipine Besylate	533	93
Losartan Potassium	Losartan Potassium	486	86
Spironolactone	Spironolactone	455	75
Metoprolol Succinate	Metoprolol Succinate	430	66
Atorvastatin Calcium	Atorvastatin Calcium	383	65
Furosemide	Furosemide	379	71
Pantoprazole Sodium	Pantoprazole Sodium	361	53
Rosuvastatin Calcium	Rosuvastatin Calcium	346	60
Allopurinol	Allopurinol	328	48
Tamsulosin Hcl	Tamsulosin Hcl	311	40
Montelukast Sodium	Montelukast Sodium	275	44
Sertraline Hcl	Sertraline Hcl	270	40
Memantine Hcl	Memantine Hcl	239	23
Duloxetine Hcl	Duloxetine Hcl	238	25
Eliquis	Apixaban	229	24
Carvedilol	Carvedilol	218	43
Albuterol Sulfate Hfa	Albuterol Sulfate	199	47
Donepezil Hcl	Donepezil Hcl	196	23
Alprazolam	Alprazolam	192	24
Metformin Hcl	Metformin Hcl	171	44
Trazodone Hcl	Trazodone Hcl	167	34
Metoprolol Tartrate	Metoprolol Tartrate	144	26
Tramadol Hcl	Tramadol Hcl	141	30
Clopidogrel	Clopidogrel Bisulfate	136	28
Pravastatin Sodium	Pravastatin Sodium	132	24
Mirtazapine	Mirtazapine	129	19
Famotidine	Famotidine	126	28
Januvia	Sitagliptin Phosphate	121	13
Metoclopramide Hcl	Metoclopramide Hcl	121	22
Ozempic	Semaglutide	117	21
Ropinirole Hcl	Ropinirole Hcl	116	17
Buspirone Hcl	Buspirone Hcl	107	18
Hydrochlorothiazide	Hydrochlorothiazide	107	23
Finasteride	Finasteride	105	17
Jardiance	Empagliflozin	105	suppressed
Omeprazole	Omeprazole	105	25
Farxiga	Dapagliflozin Propanediol	103	13
Nortriptyline Hcl	Nortriptyline Hcl	102	11
Linzess	Linaclotide	98	17
Icosapent Ethyl	Icosapent Ethyl	96	suppressed
Meloxicam	Meloxicam	96	13
Escitalopram Oxalate	Escitalopram Oxalate	95	19
Pregabalin	Pregabalin	95	15
Quetiapine Fumarate	Quetiapine Fumarate	95	14
Baclofen	Baclofen	90	12
Fluticasone Propionate	Fluticasone Propionate	90	29
Esomeprazole Magnesium	Esomeprazole Magnesium	84	13
Zolpidem Tartrate	Zolpidem Tartrate	83	17
Fentanyl	Fentanyl	82	11
Hydromorphone Hcl	Hydromorphone Hcl	81	suppressed
Vascepa	Icosapent Ethyl	75	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	74	14
Metformin Hcl Er	Metformin Hcl	74	15
Ondansetron Hcl	Ondansetron Hcl	74	31
Ezetimibe	Ezetimibe	72	13
Hydralazine Hcl	Hydralazine Hcl	71	18
Topiramate	Topiramate	71	11
Divalproex Sodium	Divalproex Sodium	70	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	69	12
Oxycodone Hcl	Oxycodone Hcl	68	suppressed
Promethazine Hcl	Promethazine Hcl	67	11
Diazepam	Diazepam	66	suppressed
Tizanidine Hcl	Tizanidine Hcl	65	11
Acetazolamide	Acetazolamide	64	12
Levetiracetam	Levetiracetam	64	12
Xarelto	Rivaroxaban	64	suppressed
Citalopram Hbr	Citalopram Hydrobromide	63	12
Lorazepam	Lorazepam	63	14
Paroxetine Hcl	Paroxetine Hcl	62	suppressed
Novolog Flexpen	Insulin Aspart	61	11
Trulicity	Dulaglutide	61	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	60	16
Hydroxyzine Hcl	Hydroxyzine Hcl	60	suppressed
Temazepam	Temazepam	60	suppressed
Aripiprazole	Aripiprazole	59	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	56	13
Simvastatin	Simvastatin	50	suppressed
Clonidine Hcl	Clonidine Hcl	49	19
Brilinta	Ticagrelor	48	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	48	11
Morphine Sulfate Er	Morphine Sulfate	47	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	46	11
Warfarin Sodium	Warfarin Sodium	46	suppressed
Lactulose	Lactulose	45	suppressed
Tresiba Flextouch U-100	Insulin Degludec	45	12
Benztropine Mesylate	Benztropine Mesylate	44	suppressed
Cephalexin	Cephalexin	44	33
Olanzapine	Olanzapine	44	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	44	suppressed
Indapamide	Indapamide	43	suppressed
Midodrine Hcl	Midodrine Hcl	43	suppressed
Ranolazine Er	Ranolazine	43	suppressed
Albuterol Sulfate	Albuterol Sulfate	42	15
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	42	33
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	42	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	41	30
Ibuprofen	Ibuprofen	41	suppressed
Prednisone	Prednisone	41	21
Primidone	Primidone	41	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	40	suppressed
Humalog Kwikpen U-100	Insulin Lispro	40	suppressed
Liothyronine Sodium	Liothyronine Sodium	40	suppressed
Gemfibrozil	Gemfibrozil	39	suppressed
Irbesartan	Irbesartan	39	suppressed
Ondansetron Odt	Ondansetron	39	11
Calcitriol	Calcitriol	38	suppressed
Levofloxacin	Levofloxacin	38	22
Belsomra	Suvorexant	37	suppressed
Bupropion Xl	Bupropion Hcl	37	suppressed
Glimepiride	Glimepiride	36	suppressed
Victoza 3-Pak	Liraglutide	35	suppressed
Latanoprost	Latanoprost	34	suppressed
Ventolin Hfa	Albuterol Sulfate	34	11
Amiodarone Hcl	Amiodarone Hcl	33	suppressed
Ipratropium Bromide	Ipratropium Bromide	33	suppressed
Myrbetriq	Mirabegron	33	suppressed
Nateglinide	Nateglinide	33	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	32	suppressed
Glipizide Er	Glipizide	32	suppressed
Alendronate Sodium	Alendronate Sodium	31	suppressed
Dayvigo	Lemborexant	31	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	31	suppressed
Breo Ellipta	Fluticasone/Vilanterol	30	suppressed
Cefdinir	Cefdinir	29	25
Hydrocortisone	Hydrocortisone	29	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	29	suppressed
Azithromycin	Azithromycin	28	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	28	suppressed
Clonazepam	Clonazepam	28	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	28	suppressed
Lithium Carbonate	Lithium Carbonate	28	suppressed
Repaglinide	Repaglinide	28	suppressed
Zenpep	Lipase/Protease/Amylase	28	suppressed
Lidocaine	Lidocaine	27	suppressed
Morphine Sulfate	Morphine Sulfate	27	suppressed
Nystatin	Nystatin	27	13
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	27	23
Triamcinolone Acetonide	Triamcinolone Acetonide	27	suppressed
Benazepril Hcl	Benazepril Hcl	26	suppressed
Celecoxib	Celecoxib	26	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	suppressed
Carisoprodol	Carisoprodol	25	suppressed
Fluconazole	Fluconazole	25	13
Meclizine Hcl	Meclizine Hcl	25	suppressed
Fenofibrate	Fenofibrate,micronized	24	suppressed
Glipizide	Glipizide	24	suppressed
Hydroxyurea	Hydroxyurea	24	suppressed
Cilostazol	Cilostazol	23	suppressed
Risperidone	Risperidone	23	suppressed
Sotalol	Sotalol Hcl	23	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	23	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	22	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Verapamil Er	Verapamil Hcl	21	suppressed
Acarbose	Acarbose	20	suppressed
Arnuity Ellipta	Fluticasone Furoate	20	suppressed
Lacosamide	Lacosamide	20	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	20	suppressed
Tradjenta	Linagliptin	20	suppressed
Dilt-Xr	Diltiazem Hcl	19	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	19	suppressed
Rybelsus	Semaglutide	19	suppressed
Varenicline Tartrate	Varenicline Tartrate	19	suppressed
Amoxicillin	Amoxicillin	18	18
Atenolol	Atenolol	18	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	18	suppressed
Calcipotriene-Betamethasone	Calcipotriene/Betamethasone	18	suppressed
Carbamazepine Er	Carbamazepine	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	18	suppressed
Lithium Carbonate Er	Lithium Carbonate	18	suppressed
Potassium Citrate Er	Potassium Citrate	18	suppressed
Estradiol	Estradiol	17	suppressed
Levemir Flexpen	Insulin Detemir	17	suppressed
Oxtellar Xr	Oxcarbazepine	17	suppressed
Sucralfate	Sucralfate	17	suppressed
Lovastatin	Lovastatin	16	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	16	suppressed
Raloxifene Hcl	Raloxifene Hcl	16	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	16	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	15	suppressed
Doxepin Hcl	Doxepin Hcl	15	suppressed
Enulose	Lactulose	15	suppressed
Invega Sustenna	Paliperidone Palmitate	15	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	15	suppressed
Mupirocin	Mupirocin	15	suppressed
Terazosin Hcl	Terazosin Hcl	15	suppressed
Sotalol Af	Sotalol Hcl	14	suppressed
Xtampza Er	Oxycodone Myristate	14	suppressed
Aimovig Autoinjector	Erenumab-Aooe	13	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	13	suppressed
Haloperidol	Haloperidol	13	suppressed
Humalog	Insulin Lispro	13	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Minoxidil	Minoxidil	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Nitroglycerin	Nitroglycerin	13	11
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	13	suppressed
Nystop	Nystatin	13	11
Penicillin V Potassium	Penicillin V Potassium	13	suppressed
Savella	Milnacipran Hcl	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Carbidopa-Levodopa-Entacapone	Carbidopa/Levodopa/Entacapone	12	suppressed
Clonidine	Clonidine	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	12	suppressed
Gentamicin Sulfate	Gentamicin Sulfate	12	suppressed
Metolazone	Metolazone	12	suppressed
Mycophenolate Mofetil	Mycophenolate Mofetil	12	suppressed
Rivastigmine	Rivastigmine	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Atrovent Hfa	Ipratropium Bromide	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Creon	Lipase/Protease/Amylase	11	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	11	suppressed
Divalproex Sodium Er	Divalproex Sodium	11	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	11	11
Dropsafe Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Entresto	Sacubitril/Valsartan	11	suppressed
Flecainide Acetate	Flecainide Acetate	11	suppressed
Gemtesa	Vibegron	11	suppressed
Propafenone Hcl	Propafenone Hcl	11	suppressed
Rivastigmine	Rivastigmine Tartrate	11	suppressed
Sodium Chloride	0.9 % Sodium Chloride	11	suppressed
Spiriva Handihaler	Tiotropium Bromide	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Timolol Maleate	Timolol Maleate	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$55.61 · 3 records	AstraZeneca Pharmaceuticals LP	FARXIGA, MOUNJARO, ZEPBOUND	5	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Farxiga play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error